Post-Earnings Review - Bed Bath and Beyond

LONDON, January 16, 2015 /PRNewswire/ --

Investor-Edge.com has issued free post-earnings review on Bed Bath & Beyond Inc. (NASDAQ: BBBY). On January 08, 2015, the company reported its financial results for Q3 FY14 (period ended November 29, 2014). Click on http://get.Investor-Edge.com/pdf/?c=Bed%20Bath%20and%20Beyond&d=16-Jan-2015&s=BBBY to read our free earnings review on Bed Bath and Beyond Inc. (Bed Bath and Beyond). During Q3 FY14, the company's net sales increased 2.7% Y-o-Y. Further, Bed Bath & Beyond's comparable sales improved 1.7% in the reported quarter. Our free coverage report can be accessed at:

http://get.Investor-Edge.com/pdf/?c=Bed%20Bath%20and%20Beyond&d=16-Jan-2015&s=BBBY

Earnings Overview  

During Q3 FY14, Bed Bath & Beyond reported net sales of approximately $2.94 billion compared with net sales of approximately $2.86 billion in Q3 FY13. The company's Q3 FY14 net sales fell short of Bloomberg analysts' forecasts of $2.97 billion. Additionally, the comparable sales growth in Q3 FY14 was approximately 1.7% compared with approximately 1.3% in Q3 FY13. Bed Bath & Beyond excluded Cost Plus World Market from the comparable sales calculations through the end of H1 FY13 and included it from beginning of Q3 FY13. The company also excluded Linen Holdings from the comparable sales calculations and it will continue to be excluded on an ongoing basis as it represents non-retail activity. The free research on BBBY can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Bed%20Bath%20and%20Beyond&d=16-Jan-2015&s=BBBY

For Q3 FY14, the company recorded net earnings of $225.41 million, or $1.23 per diluted share, compared to $237.20 million, or $1.12 per diluted share, in Q3 FY13. Analysts from Bloomberg were expecting the company to report net earnings of $219.67 million, or $1.20 per diluted share, in Q3 FY14. Additionally, net earnings per diluted share for Q3 FY14 included approximately $0.04 per share of net benefits for certain non-recurring items, including credit card fee litigation.  

In December 2014, Bed Bath & Beyond completed its $1.1 billion accelerated share repurchase program, which commenced in July 2014. As of November 29, 2014, the remaining balance of the $2.0 billion share repurchase program was approximately $1.8 billion. Sign up and read the free analyst's notes on BBBY at:

http://get.Investor-Edge.com/pdf/?c=Bed%20Bath%20and%20Beyond&d=16-Jan-2015&s=BBBY

For Q4 FY14, Bed Bath & Beyond's management expects net earnings per diluted share to be in the range of approximately $1.78 to $1.83 and also anticipates net earnings per diluted share to be in the range of approximately $5.05 to $5.09 for full year FY14.

Stock Performance 

On the day following the earnings release, January 09, 2015, Bed Bath & Beyond's stock plummeted 6.75% to end the session at $74.09. Since then, the company's stock has mostly witnessed a negative trend. On the last close, Thursday, January 15, 2015, the stock finished at $72.16, down 2.68%, after vacillating between $71.77 and $74.49. A total of 4.39 million shares were traded which was above its three months average volume of 2.59 million shares. Over the last month, the stock has lost 1.34%. However, in the last three months and in the past one year, the company's shares have gained 13.78% and 7.16%, respectively. Shares in Bed Bath & Beyond closed above their 200-day moving average of $65.53. Furthermore, the stock traded at a PE ratio of 14.76 and has a Relative Strength Index (RSI) of 48.64. Visit Investor-Edge and access the latest research on BBBY at:

http://get.Investor-Edge.com/pdf/?c=Bed%20Bath%20and%20Beyond&d=16-Jan-2015&s=BBBY

Sneak Peek to Corporate Insider Trading 

In the last one month, Bed Bath & Beyond has reported four corporate trading transactions by two insiders. On January 12, 2015, a total of 514,554 shares of the company were disposed at an average price of $73.63 per share, for a total value of $37.89 million. On the same day, Warren Eisenberg and Leonard Feinstein, Co-Chairmen at Bed Bath & Beyond, sold 199,992 and 314,562 shares, respectively, at an average price of $73.63 per share. Complimentary in-depth research on BBBY is available at:

http://get.Investor-Edge.com/pdf/?c=Bed%20Bath%20and%20Beyond&d=16-Jan-2015&s=BBBY

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge